Figure 3.

The TARGET-3 study. The left panel shows patient disposition.⁵ The right panel shows proportion of composite abdominal pain and stool consistency responders.⁶³ Response was defined as ≥30% improvement from baseline in the weekly average abdominal pain score and ≥50% reduction in the number of days per week with a daily stool consistency of Bristol Stool Scale type 6 or 7. Adapted from Xifaxan [package insert]. Salix Pharmaceuticals. Bridgewater, NJ; 2015⁵ (left panel) and Lembo AJ et al. Abstract 45. Presented at the 2014 Annual Scientific Meeting of the American College of Gastroenterology (right panel).⁶³